Aspiration Therapy As a Tool to Treat Obesity: 1- to 4-Year Results in a 201-Patient Multi-Center Post-Market European Registry Study
Open Access
- 1 February 2018
- journal article
- research article
- Published by Springer Nature in Obesity Surgery
- Vol. 28 (7) , 1860-1868
Abstract
Purpose The objective of this post-market study was to evaluate long-term safety and efficacy of aspiration therapy (AT) in a clinical setting in five European clinics. Materials and Methods The AspireAssist® System (Aspire Bariatrics, Inc. King of Prussia, PA) is an endoscopic weight loss therapy utilizing a customized percutaneous endoscopic gastrostomy tube and an external device to aspirate approximately 30% of ingested calories after a meal, in conjunction with lifestyle counseling. A total of 201 participants, with body mass index (BMI) of 35.0–70.0 kg/m2, were enrolled in this study from June 2012 to December 2016. Mean baseline BMI was 43.6 ± 7.2 kg/m2. Results Mean percent total weight loss at 1, 2, 3, and 4 years, respectively, was 18.2% ± 9.4% (n/N = 155/173), 19.8% ± 11.3% (n/N = 82/114), 21.3% ± 9.6% (n/N = 24/43), and 19.2% ± 13.1% (n/N = 12/30), where n is the number of measured participants and N is the number of participants in the absence of withdrawals or lost to follow-up. Clinically significant reductions in glycated hemoglobin (HbA1C), triglycerides, and blood pressure were observed. For participants with diabetes, HbA1C decreased by 1% (P < 0.0001) from 7.8% at baseline to 6.8% at 1 year. The only serious complications were buried bumpers, experienced by seven participants and resolved by removal/replacement of the A-Tube, and a single case of peritonitis, resolved with a 2-day course of intravenous antibiotics. Conclusion This study establishes that aspiration therapy is a safe, effective, and durable weight loss therapy in people with classes II and III obesity in a clinical setting. Trial Registration ISRCTN 49958132Keywords
Funding Information
- Scientific Commitee of Blekinge County Council Sweden
- Mina Medical AB Sweden
- Slanka Sweden AB
- Aspire Bariatrics, Inc.
- Scientific Committee of Blekinge County Council, Sweden
- Mina Medical AB, Sweden
- Slanka Sweden AB, Sweden
This publication has 23 references indexed in Scilit:
- What The Evidence Shows About Patient Activation: Better Health Outcomes And Care Experiences; Fewer Data On CostsHealth Affairs, 2013
- Multidisciplinary Practical Guidelines for Gastrointestinal Access for Enteral Nutrition and Decompression From the Society of Interventional Radiology and American Gastroenterological Association (AGA) Institute, With Endorsement by Canadian Interventional Radiological Association (CIRA) and Cardiovascular and Interventional Radiological Society of Europe (CIRSE)Gastroenterology, 2011
- Tendencia creciente de la prevalencia de obesidad mórbida en España: de 1,8 a 6,1 por mil en 14 añosRevista Espanola de Cardiologia, 2011
- Evaluation of Percutaneous Endoscopic Feeding Tube Placement in Obese PatientsNutrition in Clinical Practice, 2009
- Complications following gastrostomy tube insertion in patients with head and neck cancer: a prospective multi‐institution study, systematic review and meta‐analysisClinical Otolaryngology, 2009
- Prevalence of class I, II and III obesity in CanadaCanadian Medical Association Journal, 2006
- Care and Long‐Term Maintenance of Percutaneous Endoscopic Gastrostomy TubesJournal of Parenteral and Enteral Nutrition, 2006
- Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric SurgeryNew England Journal of Medicine, 2004
- Percutaneous Endoscopic GastrostomyAnnals of Surgery, 1993
- Percutaneous endoscopic gastrostomy: a nonoperative technique for feeding gastrostomyGastrointestinal Endoscopy, 1981